Form 4: Celularity Director Diane Parks Receives 30,000 RSU Grant

Celularity Inc. Director Diane Parks was granted 30,000 restricted stock units under the company's 2021 Equity Incentive Plan.

Summary

• Director Diane L. Parks of Celularity Inc. (CELU) was granted 30,000 restricted stock units (RSUs).
• The transaction date for this grant was January 12, 2026.
• Each RSU represents a right to receive one share of the Issuer's Class A common stock.
• These RSUs were granted under the Celularity Inc. 2021 Equity Incentive Plan.
• Following this transaction, Diane L. Parks beneficially owns 520,021 shares, which includes these 30,000 RSUs.
• The RSUs will vest on the earlier of the one-year anniversary of the grant date or the next annual stockholder meeting, contingent on continuous service.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. This is a routine compensation event that aligns director interests with shareholders, but does not indicate significant operational or financial news.

Positives

• The grant of 30,000 restricted stock units aligns the director's interests with those of shareholders, incentivizing long-term performance.
• The use of the 2021 Equity Incentive Plan demonstrates a structured approach to executive and director compensation.

Risks

• The RSUs are subject to vesting conditions, specifically continuous service with the Issuer until the vesting date. If service is terminated before vesting, the RSUs may be forfeited.
• The value of the RSUs upon vesting is dependent on the future market price of Celularity Inc.'s Class A common stock.

Future Outlook

The 30,000 RSUs granted to Director Diane L. Parks are scheduled to vest on the earlier of January 12, 2027 (one-year anniversary of the grant date) or the date of the next annual stockholder meeting, provided she maintains continuous service with Celularity Inc. until that time.

Industry Context

Restricted Stock Unit (RSU) grants are a common form of equity compensation for directors and executives across various industries, particularly in biotechnology and growth-oriented companies like Celularity Inc. They serve to align the interests of management with shareholders by tying compensation to the company's long-term performance and ensuring retention through vesting schedules.

Comparison to Industry Standards

• The grant of RSUs to a director is a standard practice in corporate compensation, comparable to similar grants at biotech companies such as Moderna, BioNTech, or Gilead Sciences, which frequently use equity to incentivize leadership.
• The vesting schedule, tied to continuous service and a one-year anniversary or next annual meeting, is also a common structure designed to promote retention and long-term commitment, aligning with best practices seen in companies across the S&P 500.

Stakeholder Impact

• Shareholders: Potential minor dilution upon vesting of the RSUs, but also improved alignment of director's interests with shareholder value creation.
• Employees: No direct impact on general employees, but reflects the company's compensation strategy for leadership.

Next Steps

• The RSUs will vest on the earlier of January 12, 2027, or the next annual stockholder meeting, subject to continuous service.

Key Dates

Keywords

Celularity Inc., CELU, Diane Parks, Form 4, Restricted Stock Units, RSU, Equity Incentive Plan, Insider Transaction, Director Compensation, Stock Grant